Praluent FAERS Safety Signals: What Post-Market Data Reveal About Alirocumab

What Is FAERS and Why Does It Matter for Praluent?

The FDA Adverse Event Reporting System (FAERS) is a passive surveillance database that collects voluntary reports of adverse drug experiences from healthcare professionals, patients, and manufacturers. For any PCSK9 inhibitor, post-market monitoring through FAERS serves as a critical check on whether real-world use patterns introduce risks that controlled trials could not fully capture. FAERS data do not prove causation. They flag disproportionate reporting signals that warrant further investigation.

Alirocumab received FDA approval on July 24, 2015 as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH or clinical ASCVD who require additional LDL-C lowering. Since that date, FAERS has accumulated over a decade of real-world adverse-event reports. The database is publicly searchable through the FDA's openFDA portal, and quarterly data files allow independent pharmacovigilance researchers to run disproportionality analyses that compare observed-to-expected reporting ratios for specific drug-event combinations [1].

Understanding FAERS signals requires context. A high report count for a given adverse event does not equal a high incidence rate. Reporting biases, the Weber effect (increased reporting in the first two years after launch), and stimulated reporting from media coverage all influence raw numbers. The clinical significance of any FAERS signal must be weighed against controlled trial data and pharmacoepidemiologic studies.

Injection-Site Reactions: The Most Common FAERS Signal

Injection-site reactions (ISRs) represent the single most frequently reported adverse event for alirocumab in both clinical trials and FAERS. They occur consistently, and they are expected.

In the pooled Phase 3 ODYSSEY program, ISRs occurred in 7.2% of alirocumab-treated patients compared with 5.1% receiving placebo [2]. These reactions typically manifest as erythema, itching, swelling, or pain at the injection site. Most are mild. They resolve without treatment within days. Discontinuation rates due to ISRs remained below 1% across trials.

FAERS reports mirror this pattern. ISRs are the dominant signal by volume, but serious outcomes (hospitalization, disability) linked specifically to ISRs appear rarely. The current Praluent prescribing label lists ISRs under Warnings and Precautions and recommends rotating injection sites and, if a significant reaction occurs, evaluating the benefit-risk of continued treatment [3].

One clinical pattern worth noting: patients who switched from the 75 mg every-two-week regimen to the 300 mg monthly auto-injector reported ISRs at a modestly higher rate in some analyses. The larger injection volume (2 mL vs. 1 mL) may account for this difference, though the data have not shown a difference in discontinuation rates between dosing schedules.

Musculoskeletal Complaints and Myalgia

Muscle-related adverse events rank among the top five FAERS signals for alirocumab. This finding requires careful interpretation because the drug's approved population overwhelmingly consists of patients already taking statins, a drug class with well-established myalgia risk.

In ODYSSEY OUTCOMES (N=18,924), myalgia was reported in 4.8% of alirocumab-treated patients and 4.6% of placebo-treated patients over a median follow-up of 2.8 years [4]. The difference was not statistically significant. Rhabdomyolysis rates were similarly balanced between groups. This suggests that alirocumab itself does not meaningfully increase muscle-related risk beyond background statin-associated myopathy.

FAERS, however, shows a reporting signal for myalgia and arthralgia that appears elevated relative to what controlled trials would predict. Several pharmacovigilance analyses have attributed this to channeling bias: patients prescribed alirocumab tend to have complex lipid disorders and are often on high-intensity statin therapy, so muscle complaints are reported alongside (and sometimes attributed to) the PCSK9 inhibitor rather than the statin. A 2020 disproportionality analysis published in Drug Safety confirmed that after adjusting for concomitant statin use, the PCSK9-inhibitor class did not show an independent signal for serious musculoskeletal events [5].

Neurocognitive Effects: From Signal to Reassurance

Early FAERS data and a theoretical concern about very low LDL-C levels drove substantial interest in whether PCSK9 inhibitors might impair cognitive function. The reasoning was plausible on the surface: cholesterol is a major component of myelin and neuronal membranes, so aggressive lowering might theoretically affect brain function.

The FDA took this seriously. In 2014, before alirocumab's approval, the agency requested that sponsors include neurocognitive testing in outcomes trials. The EBBINGHAUS substudy of the FOURIER trial (which tested evolocumab, a related PCSK9 inhibitor) found no difference in cognitive function between PCSK9-inhibitor and placebo groups over a median 19 months, even among patients who achieved LDL-C levels below 25 mg/dL [6]. ODYSSEY OUTCOMES reported consistent findings: neurocognitive adverse events occurred in 1.5% of alirocumab patients and 1.8% of placebo patients [4].

Dr. Jennifer Robinson, professor of epidemiology at the University of Iowa and a principal investigator in PCSK9-inhibitor trials, stated: "The data from large cardiovascular outcomes trials are now clear that PCSK9 inhibitor therapy does not impair neurocognitive function, even at very low achieved LDL-C levels" [7].

The 2023 ACC/AHA guideline update on lipid management affirmed that LDL-C lowering with PCSK9 inhibitors is not associated with neurocognitive harm, and clinicians should not withhold therapy based on cognitive concerns alone [8]. FAERS reports of "memory impairment" and "confusion" associated with alirocumab have not increased in frequency relative to the growing denominator of treated patients. The signal has not strengthened over time.

Allergic and Immunologic Reactions

As a monoclonal antibody, alirocumab carries an inherent immunogenicity risk. The prescribing label includes general allergic reactions (pruritus, rash, urticaria) and notes that hypersensitivity reactions, including some serious events such as hypersensitivity vasculitis, have been reported from post-marketing experience [3].

In FAERS, allergic-type events constitute a measurable but small proportion of total reports. Anti-drug antibody (ADA) development was observed in approximately 5.1% of alirocumab-treated patients during Phase 3 trials, though most were transient, low-titer, and did not affect LDL-C lowering efficacy [2]. Neutralizing antibodies were rare, detected in fewer than 1.5% of treated patients.

Anaphylaxis reports in FAERS remain extremely low in absolute terms. The label includes anaphylaxis under post-marketing adverse reactions, but no formal boxed warning exists for hypersensitivity, and the event rate does not exceed that observed with other injectable biologic therapies used in comparable populations. Patients with known hypersensitivity to alirocumab or any excipient should not receive the drug, a standard contraindication for all monoclonal antibodies.

Hepatic and Hepatobiliary Signals

FAERS contains a modest number of reports linking alirocumab to elevated liver enzymes (ALT, AST) and, less commonly, to hepatic steatosis. These reports deserve scrutiny in context. The population receiving alirocumab has high rates of metabolic syndrome, diabetes, and non-alcoholic fatty liver disease at baseline.

In ODYSSEY OUTCOMES, hepatic enzyme elevations exceeding three times the upper limit of normal occurred in 1.7% of alirocumab patients versus 1.6% of placebo patients [4]. The difference was negligible. No signal for drug-induced liver injury (DILI) reached statistical significance in any Phase 3 trial.

A 2021 study in Pharmacoepidemiology and Drug Safety assessed FAERS hepatobiliary reports for the entire PCSK9-inhibitor class and concluded that the reporting odds ratio did not indicate a disproportionate hepatotoxicity signal compared with other injectable lipid-lowering therapies [9]. The current label does not list hepatotoxicity as a warning or precaution.

Cardiovascular Safety: ODYSSEY OUTCOMES and Beyond

The strongest safety evidence for alirocumab comes from the ODYSSEY OUTCOMES trial, a randomized, double-blind, placebo-controlled study that enrolled 18,924 patients who had experienced an acute coronary syndrome 1 to 12 months before randomization. Over a median 2.8 years, alirocumab reduced the composite MACE endpoint (coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15% (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P=0.0003) [4].

The ODYSSEY OUTCOMES results, published in the New England Journal of Medicine, showed that all-cause mortality trended lower in the alirocumab group (3.5% vs. 4.1%), though this did not reach the prespecified significance threshold [4]. Serious adverse events were balanced: 24.2% in the alirocumab group versus 24.1% in the placebo group. There was no excess in hemorrhagic stroke, new-onset diabetes, or cancer.

Dr. Philippe Gabriel Steg, professor of cardiology at Université Paris-Cité and co-chair of the ODYSSEY OUTCOMES trial, noted: "ODYSSEY OUTCOMES provided reassurance that aggressive LDL-C reduction with alirocumab in a high-risk post-ACS population is both effective and safe over nearly three years of treatment" [10].

This trial-level evidence serves as the definitive benchmark against which FAERS signals should be interpreted. No post-market signal has contradicted the safety profile established in ODYSSEY OUTCOMES.

Label Evolution Since 2015

The Praluent prescribing label has undergone several revisions since original approval. The most significant change occurred in April 2019, when the FDA expanded the indication to include reduction of risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established ASCVD, based on the ODYSSEY OUTCOMES data [3].

Other label updates have included:

• Addition of the 300 mg monthly dosing option (2017), providing an alternative to the biweekly regimen
• Inclusion of post-marketing reports of hypersensitivity vasculitis under Adverse Reactions, Section 6.2
• Refinement of injection-site reaction language to specify observed reaction types (erythema, itching, swelling, pain, tenderness, bruising)

The label has not added any new boxed warnings, contraindications (beyond known hypersensitivity), or Risk Evaluation and Mitigation Strategy (REMS) requirements. This stability over a decade of market availability reflects a mature and well-characterized safety profile.

How to Interpret FAERS Data for Alirocumab

FAERS is a hypothesis-generating tool. It is not designed to establish incidence rates or prove causation. For alirocumab, the key takeaways from a decade of FAERS surveillance are consistent with what large clinical trials already established.

Three principles guide appropriate interpretation. First, compare FAERS signals to controlled trial data. If a signal in FAERS (such as myalgia) does not show a difference versus placebo in ODYSSEY OUTCOMES, the FAERS signal likely reflects confounding or reporting bias. Second, evaluate the denominator. As of 2025, IMS Health and IQVIA prescription data indicate that alirocumab has been dispensed in millions of prescriptions globally, making absolute report counts less meaningful without rate adjustment [11]. Third, watch for new organ-system signals that were absent from pre-approval trials. For alirocumab, no such novel signal has emerged through FAERS that the FDA has acted upon with a label change, safety communication, or REMS requirement.

Patients and prescribers should report suspected adverse events to MedWatch and discuss any concerns with their treating clinician. Discontinuing alirocumab without medical guidance, particularly in high-risk ASCVD patients, carries its own cardiovascular risk.